Milwaukee biotech company raises $2.5 million for trichotillomania research

Milwaukee-based Promentis Pharmaceuticals, Inc. has raised $2.5 million for the continued research of a cure for trichotillomania, a neuropsychiatric disorder affecting about 1% of the U.S. population.

People afflicted with trichotillomania pull out their own hair, causing noticeable hair loss and significantly impacting self-esteem, health, employment and quality of life.

Trichotillomania is a highly prevalent but under-recognized impulse control disorder that has no approved treatments, according to a press release.

- Advertisement -

The company recently raised $2.5 million out of a $6 million funding round, according to a Securities and Exchange Commission filing. The proceeds will be used for research, development, general corporate purposes and to compensate executive officers and certain directors.

Promentis’ lead compound, SXC-2023, is used to address glutamatergic imbalance and oxidative stress – two factors that exacerbate trichotillomania. The lead compound also has the potential to treat a wide range of adult impulse control diseases, including obsessive compulsive disorder and substance-related and addictive disorders.

In October, the company conducted a 28-patient phase 2A behavior biomarker study. The goal of the study was to demonstrate psychodynamic activity and further evaluate the safety and tolerability of SXC-2023 in adult subjects, according to a press release.

- Advertisement -

The results of the study suggest a “clear effect” associated with SXC-2023 administration in measures of impulse control closely related to trichotillomania and other indications of interest to the company. Results indicate the potential benefits of SXC-2023 on important aspects of cognitive dysfunction across a wide range of central nervous system disorders.

The company is now gearing up for a 120-patient Phase 2 multi-center trichotillomania study, which is now fully enrolled. This study will evaluate the efficacy, safety and tolerability of three oral doses of SXC -2023 in adult patients with moderate to severe trichotillomania.

Promentis held a Phase 1 clinical trial in December of 2018 and has since raised more than $26 million through investor funding.  

Sign up for the BizTimes email newsletter

Stay up-to-date on the people, companies and issues that impact business in Milwaukee and Southeast Wisconsin

What's New

BizPeople

Sponsored Content

Stay up-to-date with our free email newsletter

Keep up with the issues, companies and people that matter most to business in the Milwaukee metro area.

By subscribing you agree to our privacy policy.

No, thank you.
BizTimes Milwaukee